ReviewOncology letters2018
Antitumor mechanisms of bifidobacteria.
Review in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 47 citations in OpenAlex.
- What Does Bacteria Have to Do with Cancer? The Influence of the Body's Microbiota on Cancer in Cats and Dogs.International journal of molecular sciences · 2026Review
- Presence and copy number variations ofIranian journal of microbiology · 2026Article
- Gut microbiota centered approaches for breast cancer intervention leveraging probiotics and postbiotics.Discover oncology · 2026Review
- Mechanism of anticancer action ofOncotarget · 2025Review
- Bifidobacteria in Fermented Dairy Foods: A Health Beneficial Outlook.Probiotics and antimicrobial proteins · 2025Review
- Exploring the Immunological Role of the Microbial Composition of the Appendix and the Associated Risks of Appendectomies.Journal of personalized medicine · 2025Review
- Small Biological Fighters Against Cancer: Viruses, Bacteria, Archaea, Fungi, Protozoa, and Microalgae.Biomedicines · 2025Review
- Probiotics and the Role of Dietary Substrates in Maintaining the Gut Health: Use of Live Microbes and Their Products for Anticancer Effects against Colorectal Cancer.Journal of microbiology and biotechnology · 2024Review
- Induction of Cell Death byJournal of microbiology and biotechnology · 2024Article
- A syrup containing L-arabinose and D-xylose appears superior to PEG-4000 as a bowel cleansing agent.AMB Express · 2024Article
- Analysis of the differential expression of serum miR-21-5p, miR-135-5p, and miR-155-5p by Bifidobacterium triplex viable capsules during the perioperative stage of colorectal cancer.International journal of colorectal disease · 2024Article
- Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas.Molecular therapy. Oncology · 2024Article
- Oral microbiota: the overlooked catalyst in cancer initiation and progression.Frontiers in cell and developmental biology · 2024Review
- Multi-omics-based investigation ofFrontiers in microbiology · 2024Article
- MetaFunc: taxonomic and functional analyses of high throughput sequencing for microbiomes.Gut microbiome (Cambridge, England) · 2023Article
- Alterations in co-abundant bacteriome in colorectal cancer and its persistence after surgery: a pilot study.Scientific reports · 2022Article
- Bacterial-Based Methods for Cancer Treatment: What We Know and Where We Are.Oncology and therapy · 2022Review
- The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development.BMC microbiology · 2022Review
- Microbiota and cancer: current understanding and mechanistic implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Early-onset colorectal cancer: Current insights and future directions.World journal of gastrointestinal oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the most common causes of mortality globally. Chemotherapy, one of the major treatment strategies for cancer, primarily functions by targeting the cancer cells and affecting them physiologically, but also affects normal cells, which is a major concern at present. Therefore, adverse effects of chemotherapy drugs, including myelosuppression and liver and kidney damage, are of concern. Now, microbial products have attracted attention in cancer treatment research. Notably, carcinogenesis is considered to be associated with microbial dysbiosis, particularly the positive antitumor effects of bifidobacteria. Although there remains a substantial amount to be understood about the regulation of bifidobacteria, bifidobacteria remain an attractive and novel source of cancer therapeutics. The present review focuses on introducing the latest information on the antitumor effects of bifidobacteria and to propose future strategies for using bifidobacteria in the development of cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.